Teleflex Keeps Cardio Deals Pumping
It’s been a busy year for mergers and acquisitions in the Medical Device sector. Through December 2, 108 transactions have been announced in 2016, compared with 113 in all of 2015. Target companies specializing in cardiovascular devices make up a small percentage of those deals, but tend to post large prices. So far, $32.8 billion has been committed to three of the four transactions targeting cardiovascular products. The vast majority of that amount is the result of the $30.7 billion acquisition of St. Jude Medical (NYSE: STJ) by Abbott (NYSE: ABT), announced in April. As a result of that deal, Abbott and St. Jude agreed to sell certain vascular closure and electrophysiology assets... Read More »Boston Scientific Seeks Out Portfolio Acquisitions
Earlier this year, Boston Scientific Corporation (NYSE: BSX) acquired two companies: Cosman Medical Inc. to strengthen its neuromodulation business and EndoChoice Holdings Inc. to strengthen its pathology services and imaging technologies. Since then, the medical device giant has toned down its acquiring habits with two asset/portfolio purchases in November. On November 3, 2016, the company acquired the LumenR™ Tissue Retractor System from LumenR LLC. It is currently in development for use during endoscopic resection of lesions in the colon, esophagus or stomach. Boston Scientific will conduct additional development and evaluation of the system prior to commercialization. On November 15,... Read More »October M and A Settles into Second Place
What’s a synonym for “slowdown?” We’re as tired of writing about monthly deal volume dropping off as you probably are of reading about it. But M&A activity in October 2016 can only be summed up as slackening, declining, decelerating. Preliminary deal volume is now at the second-lowest level of the year, just 112 transactions. Only January’s deal volume was lower, at 104 transactions. We may have a few additions to October’s total as the fourth quarter grinds on, but it’s not typical to find another 15 deals. Deal value also dropped off. At $12.8 billion, it ranks as the second-lowest level of spending for the year. July 2016 still holds the honor of being the slowest month for... Read More »Medical Device Deals Pick Up in October
Only a few weeks into the fourth quarter, and five medical device deals have been announced, putting the year’s total at 95. Abbott (NYSE: ABT) and St. Jude Medical’s (NYSE: STJ) $1.12 divestiture of certain vascular closure and electrophysiology assets is among these five October deals, and the only one to disclose a price. On October 18, Terumo Corporation (OTC:TRUMF) acquired St Jude’s Angio-Seal™ and Femoseal™ vascular closure products and Abbott’s Vado® Steerable Sheath. The $1.12 billion, all-cash deal is subject to the successful completion of Abbott’s acquisition of St. Jude Medical, which was announced in April 2016. All parties involved are bound by the terms of an... Read More »Q3:16 Health Care M&A Results: Context Is Everything
Brace yourself. The third quarter results for health care mergers and acquisitions signal a hard tap on the brakes, both in deal volume and value. That’s compared with the robust second quarter, and the same quarter a year ago. Before we go any further, though, we must note that, compared with all previous third quarters stretching back to 2000, the third quarter of 2016 doesn’t look that bad. Some 369 transactions are now on the books for Q3:16, which ranks this quarter as the second-highest in deal volume for any previous third quarter. The top-ranked third quarter, coincidently, came a year ago, when Q3:15 racked up 411 transactions. So Q3:16’s deal volume slid 10% compared with the... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
